Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement

Clinical Cancer Research

Volumn 14, Issue 11, 2008, Pages 3536-3544

  Garnett, Charlie T ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; RECOMBINANT VACCINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; TAXOID;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN CELL; ANIMAL; C57BL MOUSE; DRUG EFFECT; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; HUMAN; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TAXOIDS; VACCINES, SYNTHETIC;

EID: 50349091770     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4025     Document Type: Article

References (40)

1. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82.
2. Hodge J W, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999;59:5800-7.
3. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001;61:4497-505.
4. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002;62:5770-7.
5. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22:2122 - 32.
6. Chan OT, Yang LX. The immunological effects of taxanes. Cancer Immunol Immunother 2000;49:181 -5.
7. Emens LA, Machiels JP, Reilly RT, Jaffee EM. Chemotherapy: friend or foe to cancer vaccines? Curr Opin Mol Ther 2001;3:77-84.
8. Kalechman Y, Longo DL, Catane R, et al. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int J Cancer 2000;86:281 -8.
9. Prell RA, Gearin L, Simmons A, Vanroey M, Jooss K. The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration. Cancer Immunol Immunother 2006;55:1285-93.
10. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol 2005;16:1898-905.
11. Eralp Y, Wang X,Wang JP, et al. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004;6:R275-83.
12. Eades-Perner AM, van der Putten H, Hirth A, et al. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res 1994;54:4169- 76.
13. Kass E, Schlom J, Thompson J, et al. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 1999;59:676-83.
14. Robbins PF, Kantor JA, Salgaller M, et al. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res 1991;51:3657-62.
15. Hodge JW, Schlom J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res1999;59:5106-11.
16. Kass E, Panicali DL, Mazzara G. Schlom J, Greiner JW. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen- presenting cells and acts as an immunoadjuvant. Cancer Res 2001;61:206-14.
17. Hodge JW, McLaughlin JP, KantorJA, SchlomJ. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhanceT-cell immunity and antitumor responses. Vaccine 1997;15:759-68.
18. Machiels JP, Reilly RT, Emens LA, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage- colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 2001;61:3689-97.
19. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-γ-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res 2002;62:5058-64.
20. Hughes TE. Anticancer Agents. 2nd ed. Vol. 1. Philaelphia (PA): Lippincott Williams and Wilkins:2005 p.685.
21. Rose WC, Fairchild C, Lee FY. Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 2001;47:97 -105.
22. Takeda Y, Yoshizaki I. Nonaka Y, et al. Docetaxel alone or orally combined with 5-fluorouracil and its derivatives: effects on mouse mammary tumor cell line MM2 in vitro and in vivo. Anticancer Drugs 2001;12:691 -8.
23. Chakraborty M. Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine- mediated T-cell killing. Cancer Res 2004;64:4328-37
24. Kudo-Saito C, Schlom J, Hodge JW. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005;11:2416-26.
25. von Mehren M, Arlen P, Gulley J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181 -91.
26. Emens LA. Cancer vaccines: toward the next revolution in cancer therapy. Int Rev Immunol 2006;25:259-68.
27. Arlen PM, Pazdur M, Skarupa L, Rauckhorst M. Gulley JL. A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). Clin Breast Cancer 2006;7:176-9.
28. Arlen PM. Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260 -9
29. Bogdan C, Ding A. Taxol. a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin-1 in macrophages J Leukoc Biol 1992;52:119-21
30. Burkhart CA, Berman JW, Swindell CS, Horwitz SB. Relationship between the structure of taxol and other taxanes on induction of tumor necrosis factor-α gene expression and cytotoxicity Cancer Res 1994;54:5779-82.
31. Mullms DW, Walker TM, Burger CJ, Elgert KD Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities Cancer Immunol Immunother 1997;45:20 -8.
32. Manthey CL, Perera PY, Salkowski CA, Vogel SN Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 1994;152:825-31.
33. Ojeifo JO, Wu AG, Miao Y Herscowtiz HB, Meehan KR. Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: kinetics, dose titration, and toxicity. Exp Hematol 2000;28:451 - 9.
34. Mason K, Staab A, Hunter N. et al. Enhancement of tumor radioresponse by docetaxel: Involvement of immune system. Int J Oncol 2001;18:599-606.
35. Tsavaris N, Kosmas C. Vadiaka M, Kanelopoulos P. Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 2002;87:21 -7
36. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4( + )25+ Tregulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8
37. Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955 - 9
38. Katsumata N. Docetaxel: an alternative taxane in ovarian cancer. Br J Cancer 2003;89 Suppl 3:S9-15
39. Einzig Al, Schuchter LM, Recio A, et al. Phase II trial of docetaxel (Taxotere) in patients with metastatic melanoma previously untreated with cytotoxic chemotherapy. Med Oncol 1996;13:111 -7.
40. Hitt R, Amador ML, Quintela-Fandino M, et al Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck Cancer 2006;106:106- 11.